Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• RBC Capital analyst Brian Abrahams downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) from Outperform to Sector Perform and cut the price target from $18 to $6. Aardvark Therapeutics shares closed at $12.49 on Friday. See how other analysts view this stock.
• BTIG analyst Marvin Fong downgraded Fiverr International Ltd (NYSE:FVRR) from Buy to Neutral. Fiverr Intl shares closed at $10.83 on Friday. See how other analysts view this stock.
• Morgan Stanley analyst Michael Ulz downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) from Overweight to Equal-Weight and slashed the price target from $29 to $7. Aardvark Therapeutics shares closed at $12.49 on Friday. See how other analysts view this stock.
• Goldman Sachs analyst James Quigley downgraded Novo Nordisk A/S (NYSE:NVO) from Buy to Neutral and cut the price target from $63 to $41. Novo Nordisk shares closed at $37.45 on Friday. See how other analysts view this stock.
• HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating for Aardvark Therapeutics Inc (NASDAQ:AARD) from Buy to Neutral. Aardvark Therapeutics shares closed at $12.49 on Friday. See how other analysts view this stock.

Considering buying NVO stock? Here’s what analysts think:

Photo via Shutterstock

• No comments yet. Be the first to comment!